Advantages of Developing Platform-Agnostic Gene Therapies

Video

The chief executive officer of Rocket Pharmaceuticals, Gaurav Shah, MD, discussed the company’s ex-vivo and in-vivo gene therapy platforms.

“We are platform agnostic in the sense that we develop our therapies based on high unmet need in the clinic, so we start with the end in mind. First, there are patients with rare monogenic diseases, many of whom have no treatment alternatives... There are thousands of these patients out there. Because of this philosophy, Rocket has... both an ex-vivo lentiviral platform and an in-vivo AAV platform... We want clear, clean mechanisms of action that will predict good responses with gene therapy and we want sizable enough indications to really benefit a large number of patients.”

Rocket Pharma uses both an ex-vivo lentiviral platform and in-vivo adenoviral platform to develop gene therapies for rare, monogenic diseases.

The company’s lead programs include RP-L102 (NCT04248439) for the treatment of Fanconi anemia and RP-L201 (NCT03812263) for the treatment of leukocyte adhesion deficiency-I (LAD-1), both lentiviral therapies being evaluated in phase 2 studies. 

Rocket also recently announced positive data from the phase 1 study (NCT03882437) of the adenoviral therapy RP-A501 for the treatment of Danon disease, which showed that the therapy is well-tolerated with sustained clinical benefit. The trial will continue evaluating the low-dose but not the high-dose therapy after a dose-limiting toxicity of thrombotic microangiopathy was observed.

GeneTherapyLive spoke with Gaurav Shah, MD, cofounder and chief executive officer, Rocket Pharmaceuticals, to learn more about the company’s platform-agnostic approach to creating gene therapies tailor-fit to different monogenic diseases. He discussed manufacturing and advantages of both ex-vivo and in-vivo approaches.

REFERENCE
Rocket Pharmaceuticals announces positive updates from phase 1 clinical trial of RP-A501 in Danon disease. News release. Rocket Pharmaceuticals. November 15, 2021. https://ir.rocketpharma.com/news-releases/news-release-details/rocket-pharmaceuticals-announces-positive-updates-phase-1

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.